Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
Locations
1
United States
Main Line Health
Wynnewood, Pennsylvania, United States
Start Date
August 15, 2024
Primary Completion Date
February 15, 2026
Completion Date
August 15, 2026
Last Updated
June 15, 2025
NCT07472842
NCT07471373
NCT05951452
NCT06611501
NCT07100782
NCT04806620
Lead Sponsor
Main Line Health
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions